{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:00:09Z","timestamp":1787068809490,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the development of BCR::ABL1 tyrosine kinase inhibitors (TKIs) rendered chronic myeloid leukemia (CML) a manageable condition, acquisition of drug resistance during blast phase (BP) progression remains a critical challenge. Here, we reposition FLT3, one of the most frequently mutated drivers of acute myeloid leukemia (AML), as a prognostic marker and therapeutic target of BP-CML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We generated FLT3 expressing BCR::ABL1 TKI-resistant CML cells and enrolled phase-specific CML patient cohort to obtain unpaired and paired serial specimens and verify the role of FLT3 signaling in BP-CML patients. We performed multi-omics approaches in animal and patient studies to demonstrate the clinical feasibility of FLT3 as a viable target of BP-CML by establishing the (1) molecular mechanisms of FLT3-driven drug resistance, (2) diagnostic methods of FLT3 protein expression and localization, (3) association between FLT3 signaling and CML prognosis, and (4) therapeutic strategies to tackle FLT3\n                      <jats:sup>+<\/jats:sup>\n                      CML patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We reposition the significance of FLT3 in the acquisition of drug resistance in BP-CML, thereby, newly classify a FLT3\n                      <jats:sup>+<\/jats:sup>\n                      BP-CML subgroup. Mechanistically, FLT3 expression in CML cells activated the FLT3-JAK-STAT3-TAZ-TEAD-CD36 signaling pathway, which conferred resistance to a wide range of BCR::ABL1 TKIs that was independent of recurrent BCR::ABL1 mutations. Notably, FLT3\n                      <jats:sup>+<\/jats:sup>\n                      BP-CML patients had significantly less favorable prognosis than FLT3\n                      <jats:sup>\u2212<\/jats:sup>\n                      patients. Remarkably, we demonstrate that repurposing FLT3 inhibitors combined with BCR::ABL1 targeted therapies or the single treatment with ponatinib alone can overcome drug resistance and promote BP-CML cell death in patient-derived FLT3\n                      <jats:sup>+<\/jats:sup>\n                      BCR::ABL1 cells and mouse xenograft models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Here, we reposition FLT3 as a critical determinant of CML progression via FLT3-JAK-STAT3-TAZ-TEAD-CD36 signaling pathway that promotes TKI resistance and predicts worse prognosis in BP-CML patients. Our findings open novel therapeutic opportunities that exploit the undescribed link between distinct types of malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-023-01837-4","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T01:01:48Z","timestamp":1699232508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia"],"prefix":"10.1186","volume":"22","author":[{"given":"Ji Eun","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa-Ryeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungmin","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Mi","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Tai","family":"No","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Woong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heon Yung","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Liang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Seok","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunbeom","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"1837_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O'Hare","year":"2012","unstructured":"O\u2019Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012;12:513\u201326.","journal-title":"Nat Rev Cancer"},{"key":"1837_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20:158\u201373.","journal-title":"Nat Rev Cancer"},{"key":"1837_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrclinonc.2015.193","volume":"13","author":"AJ Innes","year":"2016","unstructured":"Innes AJ, Milojkovic D, Apperley JF. Allogeneic transplantation for CML in the TKI era: striking the right balance. Nat Rev Clin Oncol. 2016;13:79\u201391.","journal-title":"Nat Rev Clin Oncol"},{"key":"1837_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann R. How I treat CML blast crisis. Blood. 2012;120:737\u201347.","journal-title":"Blood"},{"key":"1837_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","volume":"17","author":"S Soverini","year":"2018","unstructured":"Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17:49.","journal-title":"Mol Cancer"},{"key":"1837_CR6","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37:530\u201342.","journal-title":"Cancer Cell"},{"key":"1837_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004;18:189\u2013218.","journal-title":"Leukemia"},{"key":"1837_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","volume":"18","author":"H Dohner","year":"2021","unstructured":"Dohner H, Wei AH, Lowenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18:577\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"1837_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"1837_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312.","journal-title":"Leukemia"},{"key":"1837_CR11","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"1837_CR12","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","volume":"129","author":"M Levis","year":"2017","unstructured":"Levis M. Midostaurin approved for FLT3-mutated AML. Blood. 2017;129:3403\u20136.","journal-title":"Blood"},{"key":"1837_CR13","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","volume":"99","author":"JU Kazi","year":"2019","unstructured":"Kazi JU, Ronnstrand L. FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications. Physiol Rev. 2019;99:1433\u201366.","journal-title":"Physiol Rev"},{"key":"1837_CR14","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532\u201342.","journal-title":"Blood"},{"key":"1837_CR15","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1021\/acs.jproteome.9b00028","volume":"18","author":"BM Noel","year":"2019","unstructured":"Noel BM, Ouellette SB, Marholz L, Dickey D, Navis C, Yang TY, Nguyen V, Parker SJ, Bernlohr D, Sachs Z, Parker LL. Multiomic profiling of tyrosine kinase inhibitor-resistant K562 cells suggests metabolic reprogramming to promote cell survival. J Proteome Res. 2019;18:1842\u201356.","journal-title":"J Proteome Res"},{"key":"1837_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","volume":"15","author":"T Moroishi","year":"2015","unstructured":"Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15:73\u20139.","journal-title":"Nat Rev Cancer"},{"key":"1837_CR17","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/cells8060600","volume":"8","author":"HD Huh","year":"2019","unstructured":"Huh HD, Kim DH, Jeong HS, Park HW. Regulation of TEAD transcription factors in cancer biology. Cells. 2019;8:600.","journal-title":"Cells"},{"key":"1837_CR18","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41375-018-0111-3","volume":"32","author":"E Donato","year":"2018","unstructured":"Donato E, Biagioni F, Bisso A, Caganova M, Amati B, Campaner S. YAP and TAZ are dispensable for physiological and malignant haematopoiesis. Leukemia. 2018;32:2037\u201340.","journal-title":"Leukemia"},{"issue":"1","key":"1837_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12943-023-01753-7","volume":"22","author":"HD Huh","year":"2023","unstructured":"Huh HD, Sub Y, Oh J, Kim YE, Lee JY, Kim HR, Lee S, Lee H, Pak S, Amos SE, et al. Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination. Molecular Cancer. 2023;22(1):63.","journal-title":"Molecular Cancer"},{"issue":"16","key":"1837_CR20","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.3390\/cancers13164246","volume":"13","author":"J Kim","year":"2021","unstructured":"Kim J, Lim H, Moon S, Cho SY, Kim M, Park JH, Park HW, No KT. Hot spot analysis of YAP-TEAD protein-protein interaction using the fragment molecular orbital method and its application for inhibitor discovery. Cancers (Basel). 2021;13(16):4246.","journal-title":"Cancers (Basel)"},{"key":"1837_CR21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ncb3111","volume":"17","author":"JS Mo","year":"2015","unstructured":"Mo JS, Meng Z, Kim YC, Park HW, Hansen CG, Kim S, Lim DS, Guan KL. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat Cell Biol. 2015;17:500\u201310.","journal-title":"Nat Cell Biol"},{"key":"1837_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1101\/gad.173435.111","volume":"26","author":"B Zhao","year":"2012","unstructured":"Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 2012;26:54\u201368.","journal-title":"Genes Dev"},{"issue":"1304\u20131317","key":"1837_CR23","first-page":"e1305","volume":"25","author":"Y Wang","year":"2018","unstructured":"Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, et al. Comprehensive molecular characterization of the hippo signaling pathway in cancer. Cell Rep. 2018;25(1304\u20131317):e1305.","journal-title":"Cell Rep"},{"key":"1837_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","volume":"19","author":"H Ye","year":"2016","unstructured":"Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, et al. leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016;19:23\u201337.","journal-title":"Cell Stem Cell"},{"key":"1837_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3324\/haematol.2017.169946","volume":"103","author":"N Landberg","year":"2018","unstructured":"Landberg N, von Palffy S, Askmyr M, Lilljebjorn H, Sanden C, Rissler M, Mustjoki S, Hjorth-Hansen H, Richter J, Agerstam H, et al. CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting. Haematologica. 2018;103:447\u201355.","journal-title":"Haematologica"},{"key":"1837_CR26","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","volume":"10","author":"JM Gozgit","year":"2011","unstructured":"Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011;10:1028\u201335.","journal-title":"Mol Cancer Ther"},{"key":"1837_CR27","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","volume":"2007","author":"JP Radich","year":"2007","unstructured":"Radich JP. The Biology of CML blast crisis. Hematology Am Soc Hematol Educ Program. 2007;2007:384\u201391.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1837_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1756-8722-6-54","volume":"6","author":"K Sweet","year":"2013","unstructured":"Sweet K, Zhang L, Pinilla-Ibarz J. Biomarkers for determining the prognosis in chronic myelogenous leukemia. J Hematol Oncol. 2013;6:54.","journal-title":"J Hematol Oncol"},{"key":"1837_CR29","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.V80.10.2584.2584","volume":"80","author":"F Birg","year":"1992","unstructured":"Birg F, Courcoul M, Rosnet O, Bardin F, P\u00e9busque MJ, Marchetto S, Tabilio A, Mannoni P, Birnbaum D. Expression of the FMS\/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood. 1992;80:2584\u201393.","journal-title":"Blood"},{"key":"1837_CR30","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood.V87.3.1089.bloodjournal8731089","volume":"87","author":"CE Carow","year":"1996","unstructured":"Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P, Witte L, Borowitz MJ, Civin CI, Small D. Expression of the hematopoietic growth factor receptor FLT3 (STK- 1\/Flk2) in human leukemias. Blood. 1996;87:1089\u201396.","journal-title":"Blood"},{"key":"1837_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2017.01.015","volume":"54","author":"A Hattori","year":"2017","unstructured":"Hattori A, McSkimming D, Kannan N, Ito T. RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia. Leuk Res. 2017;54:47\u201354.","journal-title":"Leuk Res"},{"key":"1837_CR32","first-page":"1218","volume":"23","author":"B Xu","year":"2004","unstructured":"Xu B, Tian H, Zhou SY. Detection of FLT3 gene and FLT3\/ITD gene mutation in chronic myeloid leukemia and its significance. Ai Zheng. 2004;23:1218\u201321.","journal-title":"Ai Zheng"},{"key":"1837_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nm.3562","volume":"20","author":"F Cottini","year":"2014","unstructured":"Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014;20:599\u2013606.","journal-title":"Nat Med"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01837-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T01:01:57Z","timestamp":1699232517000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01837-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1837"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01837-4","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"assertion":[{"value":"28 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human samples were obtained from the Korea Leukemia Bank and the protocol was approved by the Institutional Review Board. Patient consent was obtained in accordance with the Declaration of Helsinki. All animal experiments were approved by the Yonsei University Institutional Animal Care and Use Committee (Documentation #201610\u2013435-02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}